Evidence map›Paper›PMID 31085270›Full record

ArticleJournal of the American Academy of Dermatology2019

Diverse presentations of cutaneous mosaicism occur in CYLD cutaneous syndrome and may result in parent-to-child transmission.

Majid Arefi, Valerie Wilson, Siobhan Muthiah, Simon Zwolinski, Dalvir Bajwa, Paul Brennan, Katie Blasdale, David Bourn, John Burn, Mauro Santibanez-Koref and 1 more

Open access · hybridAbstract read
In one paragraph

Article in Journal of the American Academy of Dermatology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.8field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Review
  3. Cutaneous mosaicism: Special considerations for women.International journal of women's dermatology · 2021
    Review
  4. Genetic Testing in CYLD Cutaneous Syndrome: An Update.The application of clinical genetics · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Majid ArefiInstitute of Genetic Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom.
Valerie WilsonClinical Genetics, Centre for Life, Newcastle upon Tyne, United Kingdom.
Siobhan MuthiahInstitute of Genetic Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom; Department of Dermatology, Royal Victoria Infirmary, Newcastle upon Tyne, United Kingdom.
Simon ZwolinskiClinical Genetics, Centre for Life, Newcastle upon Tyne, United Kingdom.
Dalvir BajwaInstitute of Genetic Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom.
Paul BrennanClinical Genetics, Centre for Life, Newcastle upon Tyne, United Kingdom.
Katie BlasdaleDepartment of Dermatology, Royal Victoria Infirmary, Newcastle upon Tyne, United Kingdom.
David BournClinical Genetics, Centre for Life, Newcastle upon Tyne, United Kingdom.
John BurnInstitute of Genetic Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom; Clinical Genetics, Centre for Life, Newcastle upon Tyne, United Kingdom.
Mauro Santibanez-KorefInstitute of Genetic Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom.
Neil RajanInstitute of Genetic Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom; Department of Dermatology, Royal Victoria Infirmary, Newcastle upon Tyne, United Kingdom. Electronic address: neil.rajan@ncl.ac.uk.
Newcastle University · GBCentre for Life · GBRoyal Victoria Infirmary · GB

Funding

Wellcome Trust
6 · The paper itself

Abstract

backgroundClusters of rare cylindroma or spiradenoma tumors are a recurrent clinical presentation, yet conventional genetic testing results in individuals with these tumors are frequently normal.

objectiveTo determine if genetic mosaicism accounts for such cases.

methodsA study of 6 cases from a series of 55 patients who met criteria for diagnostic gene testing for pathogenic CYLD variants over a 5-year period (2012-2017) was performed. A novel genetic assay was used to study DNA from peripheral blood leukocytes and, where possible, matched skin and tumor tissue.

resultsTwo patients had mosaic pathogenic CYLD variants in both the blood and skin. One of these patients transmitted a pathogenic variant to her daughter, and we report the novel phenotype of a contiguous gene deletion syndrome involving CYLD. Two patients had recurrent pathogenic variants in skin tumors from a single cluster but none detectable in the blood. LIMITATIONS: The remaining 2 patients had clinical features of mosaicism, but these cases were not solved with the assays used because of a lack of access of fresh tumor tissue.

conclusionGenetic mosaicism should be considered in patients presenting with clustered cylindromas, because this may inform genetic testing and counseling of these patients.

Indexed as

Genetic Predisposition to DiseaseAdultAgedCarcinoma, Adenoid CysticDeubiquitinating Enzyme CYLDDiagnosis, DifferentialGerm-Line MutationHumansMiddle AgedMosaicismNeoplastic Syndromes, HereditaryPolymerase Chain ReactionPrognosisRetrospective StudiesSampling StudiesSkin NeoplasmsCYLD protein, humanDeubiquitinating Enzyme CYLDBrooke-Spiegler syndromeCYLDCYLD cutaneous syndromegenetic counselinggenetic testing of the skinmosaicismparent-to-child transmission

Identifiers

PMID31085270
PMCPMC6878220
OpenAlexW2944097800

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.